Elephas

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs) respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies.